Exact Mass: 351.19803740000003

Exact Mass Matches: 351.19803740000003

Found 386 metabolites which its exact mass value is equals to given mass value 351.19803740000003, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Isatidine

retrorsine

C18H25NO6 (351.168179)


Origin: Plant; SubCategory_DNP: Alkaloids derived from ornithine, Pyrrolizidine alkaloids relative retention time with respect to 9-anthracene Carboxylic Acid is 0.363 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.358 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.361 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2325 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 177 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 117 INTERNAL_ID 147; CONFIDENCE Reference Standard (Level 1) CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 147 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 137 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 157 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 167 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 127 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 107 D000970 - Antineoplastic Agents Retrorsine is a naturally occurring toxic pyrrolizidine alkaloid. Retrorsine can bind with DNA and inhibits the proliferative capacity of hepatocytes. Retrorsine can be used for the research of hepatocellular injury[1][2]. Retrorsine is a naturally occurring toxic pyrrolizidine alkaloid. Retrorsine can bind with DNA and inhibits the proliferative capacity of hepatocytes. Retrorsine can be used for the research of hepatocellular injury[1][2].

   

trans-zeatin riboside

(2R,3R,4S,5R)-2-(6-{[(2E)-4-hydroxy-3-methylbut-2-en-1-yl]amino}-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

C15H21N5O5 (351.15426160000004)


Trans-zeatin riboside, also known as (E)-N-(4-hydroxy-3-methyl-2-butenyl)adenosine or 9-beta-D-ribofuranosyl-trans-zeatin, is a member of the class of compounds known as purine nucleosides. Purine nucleosides are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety. Trans-zeatin riboside is slightly soluble (in water) and a very weakly acidic compound (based on its pKa). Trans-zeatin riboside can be found in a number of food items such as winter squash, plains prickly pear, dill, and common buckwheat, which makes trans-zeatin riboside a potential biomarker for the consumption of these food products. D006133 - Growth Substances > D010937 - Plant Growth Regulators > D003583 - Cytokinins Acquisition and generation of the data is financially supported in part by CREST/JST. trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits. trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits. trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits.

   

Jacobine

Jacobine

C18H25NO6 (351.168179)


INTERNAL_ID 2254; CONFIDENCE Reference Standard (Level 1) CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2254 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 115 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 145 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 175 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 155 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 125 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 165 INTERNAL_ID 135; CONFIDENCE Reference Standard (Level 1) CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 135 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 105

   

Senecionine N-oxide

Integerrimine N-oxide

C18H25NO6 (351.168179)


CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2301 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 146 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 176 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 116 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 136 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 166 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 156 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 106 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 126 Senecionine n-oxide is the primary product of pyrrolizidine alkaloid biosynthesis in root cultures of Senecio vulgaris. Senecionine N-oxide has anti-cancer activity[1][2].

   

Tryprostatin B

(3S-trans)-Hexahydro-3-[[2-(3-methyl-2-butenyl)-1H-indol-3-yl]methyl]-pyrrolo[1,2-a]pyrazine-1,4-dione

C21H25N3O2 (351.194667)


A cyclic dipeptide that is brevianamide F (cyclo-L-Trp-L-Pro) substituted at position 2 on the indole ring by a prenyl group. CONFIDENCE Penicillium amphipolaria

   

O-beta-D-Xyloxylzeatin

O-beta-D-Xylosylzeatin; O-beta-D-Xyloxylzeatin

C15H21N5O5 (351.15426160000004)


   

4,21-dehydrogeissoschizine

1H-Indolo[2,3-a]quinolizin-5-ium, 3-ethylidene-2,3,6,7,12,12b-hexahydro-2-[1-(hydroxymethylene)-2-methoxy-2-oxoethyl]-, [2S-[2α(E),3E,12bβ]]-

C21H23N2O3+ (351.1708588)


An indole alkaloid that is the enol tautomer of geissoschizine, which is also dehydrogenated at the 4,21-position. 1H-Indolo[2,3-a]quinolizin-5-ium, 3-ethylidene-2,3,6,7,12,12b-hexahydro-2-[1-(hydroxymethylene)-2-methoxy-2-oxoethyl]-, [2S-[2α(E),3E,12bβ]]-. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=73385-56-5 (retrieved 2024-07-04) (CAS RN: 73385-56-5). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

   

Dipivefrin

2-[(2,2-dimethylpropanoyl)oxy]-5-[1-hydroxy-2-(methylamino)ethyl]phenyl 2,2-dimethylpropanoate

C19H29NO5 (351.20456240000004)


Dipivefrin is only found in individuals that have used or taken this drug. It is a prodrug of adrenaline, which is used to treat glaucoma. It is available as ophthalmic solution (eye drops). Dipivefrin is a prodrug with little or no pharmacologically activity until it is hydrolyzed into epinephrine inside the human eye. The liberated epinephrine, an adrenergic agonist, appears to exert its action by stimulating α- and/or β2-adrenergic receptors, leading to a decrease in aqueous production and an enhancement of outflow facility. The dipivefrin prodrug delivery system is a more efficient way of delivering the therapeutic effects of epinephrine, with fewer side effects than are associated with conventional epinephrine therapy. S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EA - Sympathomimetics in glaucoma therapy D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists C78283 - Agent Affecting Organs of Special Senses > C29705 - Anti-glaucoma Agent

   

Pirenzepine

2-[2-(4-methylpiperazin-1-yl)acetyl]-2,4,9-triazatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one

C19H21N5O2 (351.1695166)


An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as cimetidine and ranitidine. It is generally well tolerated by patients. [PubChem] A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents

   
   
   

Aniflorine

Pyrrolo[2,1-b]quinazolin-9(1H)-one, 3-[2-(dimethylamino)phenyl]-2,3-dihydro-3-hydroxy-5-methoxy-

C20H21N3O3 (351.1582836)


   

4,21-Dehydrocorynantheine aldehyde

4,21-Dehydrocorynantheine aldehyde

C21H23N2O3+ (351.1708588)


   

Tamibarotene

4-((5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl)benzoic acid

C22H25NO3 (351.18343400000003)


Tamibarotene is only found in individuals that have used or taken this drug. It is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). Tamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States.Tamibarotene is a specific agonist for retinoic acid receptor alpha/beta with possible binding to retinoid X receptors (RXR). C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent Same as: D01418

   

4-{[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid

4-{[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid

C22H25NO3 (351.18343400000003)


CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10139; ORIGINAL_PRECURSOR_SCAN_NO 10138 INTERNAL_ID 333; CONFIDENCE standard compound; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10139; ORIGINAL_PRECURSOR_SCAN_NO 10138 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10159; ORIGINAL_PRECURSOR_SCAN_NO 10156 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10167; ORIGINAL_PRECURSOR_SCAN_NO 10165 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10197; ORIGINAL_PRECURSOR_SCAN_NO 10194 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10187; ORIGINAL_PRECURSOR_SCAN_NO 10186 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10123; ORIGINAL_PRECURSOR_SCAN_NO 10122 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5493; ORIGINAL_PRECURSOR_SCAN_NO 5489 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5465; ORIGINAL_PRECURSOR_SCAN_NO 5461 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5482; ORIGINAL_PRECURSOR_SCAN_NO 5480 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5469; ORIGINAL_PRECURSOR_SCAN_NO 5467 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5500; ORIGINAL_PRECURSOR_SCAN_NO 5495 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5570; ORIGINAL_PRECURSOR_SCAN_NO 5568 D009676 - Noxae > D013723 - Teratogens D000970 - Antineoplastic Agents

   

deoxybrevianamide E

L-Prolyl-2-(1,1-dimethylallyl)-L-tryptophan anhydride

C21H25N3O2 (351.194667)


A cyclic dipeptide that is brevianamide F (cyclo-L-Trp-L-Pro) substituted at position 2 on the indole ring by a 1,1-dimethylallyl group.

   
   

Usaramine

(15E)-12,18-Dihydroxysenecionan-11,16-dione

C18H25NO6 (351.168179)


Usaramine is a pyrrolizidine alkaloid isolated from seeds of Crolatalaria pallida. Usaramine demonstrates a highlighted antibiofilm activity against Staphylococcus epidermidis by reducing more than 50\\% of biofilm formation without killing the bacteria[1]. Usaramine is a pyrrolizidine alkaloid isolated from seeds of Crolatalaria pallida. Usaramine demonstrates a highlighted antibiofilm activity against Staphylococcus epidermidis by reducing more than 50\% of biofilm formation without killing the bacteria[1].

   

ribosylzeatin

(3R,4S,5R)-2-(((E)-4-((7H-purin-6-yl)amino)-2-methylbut-2-en-1-yl)oxy)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol;trans-Zeatinriboside

C15H21N5O5 (351.15426160000004)


9-ribosyl-trans-zeatin is a 9-ribosylzeatin having trans-zeatin as the nucleobase. It has a role as a plant metabolite and a cytokinin. It is a nucleoside analogue and a 9-ribosylzeatin. It is functionally related to an adenosine. Zeatin riboside is a natural product found in Rhodococcus fascians, Pseudomonas syringae, and other organisms with data available. D006133 - Growth Substances > D010937 - Plant Growth Regulators > D003583 - Cytokinins A 9-ribosylzeatin having trans-zeatin as the nucleobase. trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits. trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits. trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits.

   

9-(beta-D-Ribofuranosyl)zeatin

2-(6-{[(2E)-4-hydroxy-3-methylbut-2-en-1-yl]amino}-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

C15H21N5O5 (351.15426160000004)


9-(beta-D-Ribofuranosyl)-(Z)-Zeatin is found in alfalfa. Zeatin is a plant hormone derived from the purine adenine. It is a member of the plant growth hormone family known as cytokinins. Zeatin was first discovered in immature corn kernels from the genus Zea. Zeatin and derivatives were discovered to be the primary active ingredient in coconut milk, which has long been known to actively induce plant growth. As in the case of kinetin, zeatin has also been reported to have several in vitro anti-aging effects on human skin fibroblasts.(Wikipedia). Isolated from many plants. (E)-Ribosylzeatin is found in many foods, some of which are cauliflower, chicory, chayote, and wild carrot. trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits. trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits. trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits.

   

Marmeline

(Z,2Z)-N-(2-hydroxy-2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)-3-phenylpropa-2-enimidic acid

C22H25NO3 (351.18343400000003)


Marmeline is found in fruits. Marmeline is an alkaloid from the leaves and unripe fruits of Aegle marmelos (bael

   

Phenylalanyltryptophan

(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C20H21N3O3 (351.1582836)


Phenylalanyltryptophan is a dipeptide composed of phenylalanine and tryptophan. It is an incomplete breakdown product of protein digestion or protein catabolism. Dipeptides are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Some dipeptides are known to have physiological or cell-signalling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. H-Phe-Trp-OH (Phenylalanyltryptophan) is an endogenous metabolite[1]. H-Phe-Trp-OH (Phenylalanyltryptophan) is an endogenous metabolite[1].

   

Tryptophyl-Phenylalanine

2-{[2-amino-1-hydroxy-3-(1H-indol-3-yl)propylidene]amino}-3-phenylpropanoate

C20H21N3O3 (351.1582836)


Tryptophyl-Phenylalanine is a dipeptide composed of tryptophan and phenylalanine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

   

Sphingosine 1-phosphate (d16:1-P)

{[(2S,3R,4E)-2-amino-3-hydroxyhexadec-4-en-1-yl]oxy}phosphonic acid

C16H34NO5P (351.2174484)


Sphingosine 1-phosphate (d16:1-P) is a Sphingosine-1-phosphate. Sphingosine-1-phosphate is a signaling sphingolipid. It is also referred to as a bioactive lipid mediator. Sphingolipids at large form a class of lipids characterized by a particular aliphatic aminoalcohol, which is sphingosine. (Wikipedia)

   

Trideca-3,6,9-trienoylcarnitine

3-(trideca-3,6,9-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C20H33NO4 (351.2409458000001)


Trideca-3,6,9-trienoylcarnitine is an acylcarnitine. More specifically, it is an trideca-3,6,9-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Trideca-3,6,9-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Trideca-3,6,9-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Trideca-6,8,10-trienoylcarnitine

3-(trideca-6,8,10-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C20H33NO4 (351.2409458000001)


Trideca-6,8,10-trienoylcarnitine is an acylcarnitine. More specifically, it is an trideca-6,8,10-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Trideca-6,8,10-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Trideca-6,8,10-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Trideca-7,9,11-trienoylcarnitine

3-(trideca-7,9,11-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C20H33NO4 (351.2409458000001)


Trideca-7,9,11-trienoylcarnitine is an acylcarnitine. More specifically, it is an trideca-7,9,11-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Trideca-7,9,11-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Trideca-7,9,11-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Trideca-3,5,7-trienoylcarnitine

3-(trideca-3,5,7-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C20H33NO4 (351.2409458000001)


Trideca-3,5,7-trienoylcarnitine is an acylcarnitine. More specifically, it is an trideca-3,5,7-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Trideca-3,5,7-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Trideca-3,5,7-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Trideca-5,7,9-trienoylcarnitine

3-(trideca-5,7,9-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C20H33NO4 (351.2409458000001)


Trideca-5,7,9-trienoylcarnitine is an acylcarnitine. More specifically, it is an trideca-5,7,9-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Trideca-5,7,9-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Trideca-5,7,9-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(3E,5E,9E)-Trideca-3,5,9-trienoylcarnitine

3-(trideca-3,5,9-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C20H33NO4 (351.2409458000001)


(3E,5E,9E)-Trideca-3,5,9-trienoylcarnitine is an acylcarnitine. More specifically, it is an (3E,5E,9E)-trideca-3,5,9-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3E,5E,9E)-Trideca-3,5,9-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (3E,5E,9E)-Trideca-3,5,9-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Trideca-4,6,8-trienoylcarnitine

3-(trideca-4,6,8-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C20H33NO4 (351.2409458000001)


Trideca-4,6,8-trienoylcarnitine is an acylcarnitine. More specifically, it is an trideca-4,6,8-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Trideca-4,6,8-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Trideca-4,6,8-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Trideca-4,7,10-trienoylcarnitine

3-(trideca-4,7,10-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C20H33NO4 (351.2409458000001)


Trideca-4,7,10-trienoylcarnitine is an acylcarnitine. More specifically, it is an trideca-4,7,10-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Trideca-4,7,10-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Trideca-4,7,10-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Trideca-2,5,8-trienoylcarnitine

3-(trideca-2,5,8-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C20H33NO4 (351.2409458000001)


Trideca-2,5,8-trienoylcarnitine is an acylcarnitine. More specifically, it is an trideca-2,5,8-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Trideca-2,5,8-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Trideca-2,5,8-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Trideca-2,4,6-trienoylcarnitine

3-(trideca-2,4,6-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C20H33NO4 (351.2409458000001)


Trideca-2,4,6-trienoylcarnitine is an acylcarnitine. More specifically, it is an trideca-2,4,6-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Trideca-2,4,6-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Trideca-2,4,6-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Trideca-5,8,11-trienoylcarnitine

3-(trideca-5,8,11-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C20H33NO4 (351.2409458000001)


Trideca-5,8,11-trienoylcarnitine is an acylcarnitine. More specifically, it is an trideca-5,8,11-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Trideca-5,8,11-trienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Trideca-5,8,11-trienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(1R,4E,6S,7S,17R)-4-Ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-2,9-dioxa-14-azatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione

(1R,4E,6S,7S,17R)-4-Ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-2,9-dioxa-14-azatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione

C18H25NO6 (351.168179)


   

(2R,3S,5R)-2-[6-[[(1S,2S)-2-Hydroxycyclopentyl]amino]-9-purinyl]-5-(hydroxymethyl)oxolane-3,4-diol

(2R,3S,5R)-2-[6-[[(1S,2S)-2-Hydroxycyclopentyl]amino]-9-purinyl]-5-(hydroxymethyl)oxolane-3,4-diol

C15H21N5O5 (351.15426160000004)


   

Phenol, 2-(2H-benzotriazol-2-yl)-4,6-bis(1,1-dimethylpropyl)-

2-(2H-1,2,3-benzotriazol-2-yl)-4,6-bis(2-methylbutan-2-yl)phenol

C22H29N3O (351.2310504)


   

6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide

6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methylpyridine-3-carboxamide

C21H25N3O2 (351.194667)


GSK189254A (GSK189254 free base) is a novel, potent and selective histamine H3 receptor antagonist with pKi values of 9.59-9.90 and 8.51-9.17 for human and rat H3, respectively.

   

2-Amino-6-[2-[3-(3-methoxyphenyl)phenyl]ethyl]-3,6-dimethyl-5H-pyrimidin-4-one

2-amino-6-(2-{3-methoxy-[1,1-biphenyl]-3-yl}ethyl)-3,6-dimethyl-3,4,5,6-tetrahydropyrimidin-4-one

C21H25N3O2 (351.194667)


   

Estradiol sulfamate

(17-Hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl) sulfamate

C18H25NO4S (351.15042100000005)


   

N-[(6R)-6-(Dimethylamino)-6,7,8,9-tetrahydro-5H-carbazol-3-yl]-4-fluorobenzamide

N-[(6R)-6-(Dimethylamino)-6,7,8,9-tetrahydro-5H-carbazol-3-yl]-4-fluorobenzamide

C21H22FN3O (351.1746814)


   

4-Fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide

4-Fluoro-N-(3-(1-methyl-4-piperidinyl)-1H-indol-5-yl)benzamide

C21H22FN3O (351.1746814)


   

Pyrrolifene

1,2-Diphenyl-3-[(pyrrolidin-1-yl)methyl]butan-2-yl acetic acid

C23H29NO2 (351.2198174)


   

Senecionine N-oxide

4-ethylidene-7-hydroxy-6,7-dimethyl-3,8-dioxo-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-en-14-ium-14-olate

C18H25NO6 (351.168179)


   

Benzeneacetic acid, 4-(2-(diethylamino)-2-oxoethoxy)-3-ethoxy-, propyl ester

Benzeneacetic acid, 4-(2-(diethylamino)-2-oxoethoxy)-3-ethoxy-, propyl ester

C19H29NO5 (351.20456240000004)


   

N-[1-[4-[(4-Pyrimidin-2-ylpiperazin-1-yl)methyl]phenyl]cyclopropyl]acetamide

N-[1-(4-{[4-(pyrimidin-2-yl)piperazin-1-yl]methyl}phenyl)cyclopropyl]ethanimidate

C20H25N5O (351.2059)


   

cis-zeatin riboside

2-(6-{[(2Z)-4-hydroxy-3-methylbut-2-en-1-yl]amino}-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

C15H21N5O5 (351.15426160000004)


Cis-zeatin riboside is a member of the class of compounds known as purine nucleosides. Purine nucleosides are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety. Cis-zeatin riboside is slightly soluble (in water) and a very weakly acidic compound (based on its pKa). Cis-zeatin riboside can be found in a number of food items such as american pokeweed, sesbania flower, moth bean, and common chokecherry, which makes cis-zeatin riboside a potential biomarker for the consumption of these food products.

   

1ST14176

(5R,6R,9a1R,14aR,Z)-3-ethylidene-6-hydroxy-5,6-dimethyl-2,7-dioxo-2,3,4,5,6,7,9,9a1,11,13,14,14a-dodecahydro-12H-[1,6]dioxacyclododecino[2,3,4-gh]pyrrolizine 12-oxide

C18H25NO6 (351.168179)


Senecionine N-oxide is a tertiary amine oxide. It is functionally related to a senecionine. Senecionine N-oxide is a natural product found in Dorobaea pimpinellifolia, Senecio gallicus, and other organisms with data available. Senecionine n-oxide is the primary product of pyrrolizidine alkaloid biosynthesis in root cultures of Senecio vulgaris. Senecionine N-oxide has anti-cancer activity[1][2].

   

Ursamine

[1,6]Dioxacyclododecino[2,3,4-gh]pyrrolizine-2,7-dione, 3-ethylidene-3,4,5,6,9,11,13,14,14a,14b-decahydro-6-hydroxy-6-(hydroxymethyl)-5-methyl-, (3E,5R,6S,14aR,14bR)-

C18H25NO6 (351.168179)


LSM-2938 is a macrolide. Usaramine is a natural product found in Senecio malacitanus, Senecio ceratophylloides, and other organisms with data available. D000970 - Antineoplastic Agents Usaramine is a pyrrolizidine alkaloid isolated from seeds of Crolatalaria pallida. Usaramine demonstrates a highlighted antibiofilm activity against Staphylococcus epidermidis by reducing more than 50\\% of biofilm formation without killing the bacteria[1]. Usaramine is a pyrrolizidine alkaloid isolated from seeds of Crolatalaria pallida. Usaramine demonstrates a highlighted antibiofilm activity against Staphylococcus epidermidis by reducing more than 50\% of biofilm formation without killing the bacteria[1].

   

Usaramin

[1,6]Dioxacyclododecino[2,3,4-gh]pyrrolizine-2,7-dione, 3-ethylidene-3,4,5,6,9,11,13,14,14a,14b-decahydro-6-hydroxy-6-(hydroxymethyl)-5-methyl-, (3E,5R,6S,14aR,14bR)-

C18H25NO6 (351.168179)


LSM-2938 is a macrolide. Usaramine is a natural product found in Senecio malacitanus, Senecio ceratophylloides, and other organisms with data available. D000970 - Antineoplastic Agents Usaramine is a pyrrolizidine alkaloid isolated from seeds of Crolatalaria pallida. Usaramine demonstrates a highlighted antibiofilm activity against Staphylococcus epidermidis by reducing more than 50\\% of biofilm formation without killing the bacteria[1]. Usaramine is a pyrrolizidine alkaloid isolated from seeds of Crolatalaria pallida. Usaramine demonstrates a highlighted antibiofilm activity against Staphylococcus epidermidis by reducing more than 50\% of biofilm formation without killing the bacteria[1].

   

9-Ribosyl-cis-zeatin

6-(4-Hydroxy-3-methyl-cis-2-butenylamino)-9-beta-D-ribofuranosylpurine

C15H21N5O5 (351.15426160000004)


   
   
   

(12S)-12-hydroxyretroisosenine

(12S)-12-hydroxyretroisosenine

C18H25NO6 (351.168179)


   

Gynuramine

19-Hydroxysenecionine

C18H25NO6 (351.168179)


   

Stemonidine

8-methoxy-3-methyl-3-(4-methyl-5-oxooxolan-2-yl)spiro[1,2,3,5,6,7,8,9a-octahydropyrrolo[1,2-a]azepine-9,5-oxolane]-2-one

C19H29NO5 (351.20456240000004)


CID 5250922 is a natural product found in Stemona japonica with data available.

   

3,4,5,6-Tetradehydroyohimbine

3,4,5,6-Tetradehydroyohimbine

C21H23N2O3 (351.1708588)


   
   
   
   
   

2-(2H-Benzo[d][1,2,3]triazol-2-yl)-4,6-di-tert-pentylphenol

2-(2H-Benzo[d][1,2,3]triazol-2-yl)-4,6-di-tert-pentylphenol

C22H29N3O (351.2310504)


   
   
   

Senecivernine N-oxide

(1R,5R,6R,7R,17R)-7-hydroxy-5,6,7-trimethyl-4-methylidene-14-oxido-2,9-dioxa-14-azoniatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione

C18H25NO6 (351.168179)


A pyrrolizine alkaloid that is produced by a hybrid species of Jacobaea. CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2280

   

3alpha-mesaconyloxy-6beta-senecioyloxytropane

3alpha-mesaconyloxy-6beta-senecioyloxytropane

C18H25NO6 (351.168179)


   

(+)-3alpha-(3,4,5-trimethoxybenzoyloxy)tropan-6beta-ol|3alpha-(3,4,5-Trimethoxybenzoyloxy)tropan-6beta-ol

(+)-3alpha-(3,4,5-trimethoxybenzoyloxy)tropan-6beta-ol|3alpha-(3,4,5-Trimethoxybenzoyloxy)tropan-6beta-ol

C18H25NO6 (351.168179)


   
   
   

N,N-Dimethylnaamine D

N,N-Dimethylnaamine D

C21H25N3O2 (351.194667)


   
   
   
   

22N-Tetrahydroalstonin|4-methyl-3,4,4a,5,7,8,13,13b,14,14a-decahydro-indolo[2,3:3,4]pyrido[1,2-b][2,7]naphthyridine-1-carboxylic acid ethyl ester

22N-Tetrahydroalstonin|4-methyl-3,4,4a,5,7,8,13,13b,14,14a-decahydro-indolo[2,3:3,4]pyrido[1,2-b][2,7]naphthyridine-1-carboxylic acid ethyl ester

C21H25N3O2 (351.194667)


   
   
   
   

12,13-(Xi)-ethane-1,1-diyldioxy-(13betaH,14betaH)-14,19-dihydro-20-nor-crotalanane-11,15-dione|Monocrotalinin|Monocrotalinine|O,O-(Xi)-ethane-1,1-diyl-monocrotaline

12,13-(Xi)-ethane-1,1-diyldioxy-(13betaH,14betaH)-14,19-dihydro-20-nor-crotalanane-11,15-dione|Monocrotalinin|Monocrotalinine|O,O-(Xi)-ethane-1,1-diyl-monocrotaline

C18H25NO6 (351.168179)


   
   
   
   
   
   
   

castanospermine-8-O-beta-D-glucopyranoside

castanospermine-8-O-beta-D-glucopyranoside

C14H25NO9 (351.152924)


   

3-[1-(3-methyl-but-2-enyl)-indol-3-ylmethyl]-hexahydro-pyrrolo[1,2-a]pyrazine-1,4-dione|cyclo(N-prenyl-L-tryptophyl-L-prolyl)|Cyclo-L-prolyl-L-|N-prenyl-cyclo-L-tryptophyl-L-proline

3-[1-(3-methyl-but-2-enyl)-indol-3-ylmethyl]-hexahydro-pyrrolo[1,2-a]pyrazine-1,4-dione|cyclo(N-prenyl-L-tryptophyl-L-prolyl)|Cyclo-L-prolyl-L-|N-prenyl-cyclo-L-tryptophyl-L-proline

C21H25N3O2 (351.194667)


   
   
   

1-epi-australine-2-O-beta-D-glucopyranoside

1-epi-australine-2-O-beta-D-glucopyranoside

C14H25NO9 (351.152924)


   

8-Azabicyclo[3.2.1]octane-3,6-diol, 8-methyl-2-(phenylmethyl)-, 6-benzoate

8-Azabicyclo[3.2.1]octane-3,6-diol, 8-methyl-2-(phenylmethyl)-, 6-benzoate

C22H25NO3 (351.18343400000003)


   

(13R)-13-hydroxyretroisosenine

(13R)-13-hydroxyretroisosenine

C18H25NO6 (351.168179)


   
   
   
   
   
   
   
   
   
   
   
   

JWH 250 5-hydroxyindole metabolite

JWH 250 5-hydroxyindole metabolite

C22H25NO3 (351.18343400000003)


   
   
   
   
   

JWH 250 N-(5-hydroxypentyl) metabolite

JWH 250 N-(5-hydroxypentyl) metabolite

C22H25NO3 (351.18343400000003)


   

(S)-2-((S)-3-(1H-Imidazol-4-yl)-2-((S)-pyrrolidine-2-carboxamido)Propanamido)-3-methylbutanoic acid

(S)-2-((S)-3-(1H-Imidazol-4-yl)-2-((S)-pyrrolidine-2-carboxamido)Propanamido)-3-methylbutanoic acid

C16H25N5O4 (351.190645)


   
   
   
   
   

Jacobine

SPIRO((1,6)DIOXACYCLODODECINO(2,3,4-GH)PYRROLIZINE-3(2H),2-OXIRANE)-2,7(4H)-DIONE, 5,6,9,11,13,14,14A,14B-OCTAHYDRO-6-HYDROXY-3,5,6-TRIMETHYL-, (2S,3S,5R,6R,14AR,14BR)-

C18H25NO6 (351.168179)


Jacobine is a pyrrolizine alkaloid. Jacobine is a natural product found in Crotalaria micans, Senecio brasiliensis, and other organisms with data available.

   

Integerrimine N-oxide

(1R,4E,6R,7R,17R)-4-ethylidene-7-hydroxy-6,7-dimethyl-14-oxido-2,9-dioxa-14-azoniatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione

C18H25NO6 (351.168179)


Integerrimine N-oxide is a natural product found in Senecio nebrodensis and Senecio brasiliensis with data available.

   

1ST40320

(1,6)Dioxacyclododecino(2,3,4-gh)pyrrolizine-2,7-dione, 3-ethylidene-3,4,5,6,9,11,13,14,14a,14b-decahydro-6-hydroxy-6-(hydroxymethyl)-5-methyl-, (3Z,5R,6S,14aR,14bR)-

C18H25NO6 (351.168179)


Retrorsine is a macrolide. Retrorsine is a natural product found in Crotalaria spartioides, Senecio malacitanus, and other organisms with data available. D000970 - Antineoplastic Agents Retrorsine is a naturally occurring toxic pyrrolizidine alkaloid. Retrorsine can bind with DNA and inhibits the proliferative capacity of hepatocytes. Retrorsine can be used for the research of hepatocellular injury[1][2]. Retrorsine is a naturally occurring toxic pyrrolizidine alkaloid. Retrorsine can bind with DNA and inhibits the proliferative capacity of hepatocytes. Retrorsine can be used for the research of hepatocellular injury[1][2].

   

9-Ribosyl-trans-zeatin

9-Ribosyl-trans-zeatin

C15H21N5O5 (351.15426160000004)


CONFIDENCE standard compound; ML_ID 23

   

Cis-Zeatin-riboside-[d5]

Cis-Zeatin-riboside-[d5]

C15H21N5O5 (351.15426160000004)


Acquisition and generation of the data is financially supported by the Max-Planck-Society

   

Cis-Zeatin-riboside

Cis-Zeatin-riboside

C15H21N5O5 (351.15426160000004)


Acquisition and generation of the data is financially supported by the Max-Planck-Society

   

trans-Zeatin-riboside

trans-Zeatin-riboside

C15H21N5O5 (351.15426160000004)


Acquisition and generation of the data is financially supported by the Max-Planck-Society

   

Trans-Zeatin-riboside-[d5]

Trans-Zeatin-riboside-[d5]

C15H21N5O5 (351.15426160000004)


Acquisition and generation of the data is financially supported by the Max-Planck-Society

   

Trans-zeatin riboside

N-(4-hydroxy-3-methyl-2-butenyl)adenosine

C15H21N5O5 (351.15426160000004)


trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits. trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits. trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits.

   

9-ribosylzeatin

trans-Zeatin-riboside

C15H21N5O5 (351.15426160000004)


relative retention time with respect to 9-anthracene Carboxylic Acid is 0.545 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.538 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.540

   

MLS002153926-01!Retrorsine480-54-6

MLS002153926-01!Retrorsine480-54-6

C18H25NO6 (351.168179)


   
   
   

retrorsine

retrorsine

C18H25NO6 (351.168179)


Annotation level-1

   

3,N4-Hydroxy-epoxyoctenal-deoxycytidine

3,N4-Hydroxy-epoxyoctenal-deoxycytidine

C17H25N3O5 (351.179412)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

(S)-8-(2-hydroxy-2,2-diphenylacetoxy)-1-methyl-1-azoniabicyclo[2.2.2]octane

(S)-8-(2-hydroxy-2,2-diphenylacetoxy)-1-methyl-1-azoniabicyclo[2.2.2]octane

C22H25NO3 (351.18343400000003)


   
   

N-3-oxo-hexadec-11(Z)-enoyl-L-Homoserine lactone

3-oxo-N-[(3S)-tetrahydro-2-oxo-3-furanyl]-(11Z)-hexadecenamide

C20H33NO4 (351.2409458000001)


   

Capnine

(2R,3R)-2-amino-3-hydroxy-15-methylhexadecane-1-sulfonic acid

C17H37NO4S (351.2443162)


   

JWH 250 N-(4-hydroxypentyl) metabolite

JWH 250 N-(4-hydroxypentyl) metabolite

C22H25NO3 (351.18343400000003)


   

Phe-TRP

2-[2-amino-3-(1H-indol-3-yl)propanamido]-3-phenylpropanoic acid

C20H21N3O3 (351.1582836)


A dipeptide formed from L-phenylalanine and L-tryptophan residues.

   

TRP-Phe

2-(2-amino-3-phenylpropanamido)-3-(1H-indol-3-yl)propanoic acid

C20H21N3O3 (351.1582836)


A dipeptide formed from L-tryptophan and L-phenylalanine residues.

   

Marmeline

(2Z)-N-(2-hydroxy-2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)-3-phenylprop-2-enamide

C22H25NO3 (351.18343400000003)


   

ribosylzeatin

2-(6-{[(2E)-4-hydroxy-3-methylbut-2-en-1-yl]amino}-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

C15H21N5O5 (351.15426160000004)


trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits. trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits. trans-Zeatinriboside is a type of cytokinin precursor, acts as a major long-distance signalling form in xylem vessels, regulates leaf size and meristem activity-related traits.

   

3O-C16:1-HSL

N-(3-oxo-9Z-hexadecenoyl)-homoserine lactone

C20H33NO4 (351.2409458000001)


   

SPBP 16:1;O2

Hexadecaphing-4-enine-1-phosphate

C16H34NO5P (351.2174484)


   
   

4-{2-[3-(2-Furyl)phenyl]ethyl}-6-(3-methylbutoxy)-2-pyrimidinamin e

4-{2-[3-(2-Furyl)phenyl]ethyl}-6-(3-methylbutoxy)-2-pyrimidinamin e

C21H25N3O2 (351.194667)


   

1-Benzyl 5-methyl N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-glutam ate

1-Benzyl 5-methyl N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-glutam ate

C18H25NO6 (351.168179)


   

1-Benzyl 5-methyl N-{[(2-methyl-2-propanyl)oxy]carbonyl}-D-glutam ate

1-Benzyl 5-methyl N-{[(2-methyl-2-propanyl)oxy]carbonyl}-D-glutam ate

C18H25NO6 (351.168179)


   

endo-8-Methyl-8-azabicyclo[3.2.1]octan-3-yl 2-hydroxy-2,2-diphenylacetate

endo-8-Methyl-8-azabicyclo[3.2.1]octan-3-yl 2-hydroxy-2,2-diphenylacetate

C22H25NO3 (351.18343400000003)


   

moquizone

moquizone

C20H21N3O3 (351.1582836)


C78276 - Agent Affecting Digestive System or Metabolism > C66913 - Cholagogues or Choleretic Agents

   

4-CYANO-3-FLUOROPHENYL 4-(TRANS-4-ETHYLCYCLOHEXYL)-BENZOATE

4-CYANO-3-FLUOROPHENYL 4-(TRANS-4-ETHYLCYCLOHEXYL)-BENZOATE

C22H22FNO2 (351.1634484)


   

4-(1-BOC-piperidin-4-yloxy)-2-methoxyphenylboronic acid

4-(1-BOC-piperidin-4-yloxy)-2-methoxyphenylboronic acid

C17H26BNO6 (351.1853086)


   

4-(1-BOC-piperidin-4-yloxy)-3-methoxyphenylboronic acid

4-(1-BOC-piperidin-4-yloxy)-3-methoxyphenylboronic acid

C17H26BNO6 (351.1853086)


   

TERT-BUTYL ((S)-1-((S)-2-CARBAMOYLPYRROLIDIN-1-YL)-3-(1H-IMIDAZOL-4-YL)-1-OXOPROPAN-2-YL)CARBAMATE

TERT-BUTYL ((S)-1-((S)-2-CARBAMOYLPYRROLIDIN-1-YL)-3-(1H-IMIDAZOL-4-YL)-1-OXOPROPAN-2-YL)CARBAMATE

C16H25N5O4 (351.190645)


   

Pipoxolan

Pipoxolan Hcl

C22H25NO3 (351.18343400000003)


C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent

   

Urea, N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]-N-cyclohexyl- (9CI)

Urea, N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]-N-cyclohexyl- (9CI)

C20H25N5O (351.2059)


   

(S)-(+)-2-DIBENZYLAMINO-3-PHENYL-1-PROPANOL

(S)-(+)-2-DIBENZYLAMINO-3-PHENYL-1-PROPANOL

C22H25NO3 (351.18343400000003)


   

2-(2-Hydroxy-3,5-dipentylphenyl)benzotriazole

2-(2-Hydroxy-3,5-dipentylphenyl)benzotriazole

C22H29N3O (351.2310504)


   
   

3-(2,2-DIETHOXY-ETHOXY)-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER

3-(2,2-DIETHOXY-ETHOXY)-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER

C19H29NO5 (351.20456240000004)


   

2,4,6-trip-tolyl-1,3,5-triazine

2,4,6-trip-tolyl-1,3,5-triazine

C24H21N3 (351.17353860000003)


   

1H-​Benzimidazole-​5-​carboxylic acid, 2-​[[[4-​(aminoiminomethyl)​phenyl]​amino]​methyl]​-​1-​methyl-​, ethyl ester

1H-​Benzimidazole-​5-​carboxylic acid, 2-​[[[4-​(aminoiminomethyl)​phenyl]​amino]​methyl]​-​1-​methyl-​, ethyl ester

C19H21N5O2 (351.1695166)


   
   

N-[(2-Methyl-1H-benzimidazol-1-yl)acetyl]-L-phenylalanine

N-[(2-Methyl-1H-benzimidazol-1-yl)acetyl]-L-phenylalanine

C20H21N3O3 (351.1582836)


   

sodium N-(2-carboxyethyl)-N-dodecyl-beta-alaninate

sodium N-(2-carboxyethyl)-N-dodecyl-beta-alaninate

C18H34NNaO4 (351.23854040000003)


   

1,3,5-Tris(4-aminophenyl)benzene

1,3,5-Tris(4-aminophenyl)benzene

C24H21N3 (351.17353860000003)


   

5-[4-(TERT-BUTYL)PHENYL]-4-(4-ISOPROPYLPHENYL)-4H-1,2,4-TRIAZOLE-3-THIOL

5-[4-(TERT-BUTYL)PHENYL]-4-(4-ISOPROPYLPHENYL)-4H-1,2,4-TRIAZOLE-3-THIOL

C21H25N3S (351.176909)


   

(1R,2S)-trans-2-(Fmoc-aminomethyl)cyclohexanol

(1R,2S)-trans-2-(Fmoc-aminomethyl)cyclohexanol

C22H25NO3 (351.18343400000003)


   

1-TERT-BUTYL 2-METHYL 4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1H-PYRROLE-1,2-DICARBOXYLATE

1-TERT-BUTYL 2-METHYL 4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1H-PYRROLE-1,2-DICARBOXYLATE

C17H26BNO6 (351.1853086)


   

sebacic acid, compound with 2,2,2-nitrilotriethanol

sebacic acid, compound with 2,2,2-nitrilotriethanol

C16H33NO7 (351.2256908)


   

Fendiline Hydrochloride

Fendiline Hydrochloride

C23H26ClN (351.1753666000001)


D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators

   

Devaleryl Valsartan Impurity

Devaleryl Valsartan Impurity

C19H21N5O2 (351.1695166)


   

N,N,N-TRIPHENYL-1,3,5-BENZENETRIAMINE

N,N,N-TRIPHENYL-1,3,5-BENZENETRIAMINE

C24H21N3 (351.17353860000003)


   

1,5-Pentanediaminium,N1,N1,N1,N5,N5,N5-hexaethyl-, bromide (1:2)

1,5-Pentanediaminium,N1,N1,N1,N5,N5,N5-hexaethyl-, bromide (1:2)

C17H40BrN2+ (351.237468)


   

(1S,2R)-trans-2-(Fmoc-aminomethyl)cyclohexanol

(1S,2R)-trans-2-(Fmoc-aminomethyl)cyclohexanol

C22H25NO3 (351.18343400000003)


   

Pyrrolifene

Pyrrolifene

C23H29NO2 (351.2198174)


C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent

   

4-(4-(4-(4-METHOXYPHENYL)PIPERAZIN-1-YL)PHENYL)-1H-1,2,4-TRIAZOL-5(4H)-ONE

4-(4-(4-(4-METHOXYPHENYL)PIPERAZIN-1-YL)PHENYL)-1H-1,2,4-TRIAZOL-5(4H)-ONE

C19H21N5O2 (351.1695166)


   

Solvent Orange 14

Solvent Orange 14

C22H17N5 (351.1483882)


   

N,N-DIMETHYL-N-DODECYL-N-(2-HYDROXY-3-SULFOPROPYL)AMMONIUM BETAINE

N,N-DIMETHYL-N-DODECYL-N-(2-HYDROXY-3-SULFOPROPYL)AMMONIUM BETAINE

C17H37NO4S (351.2443162)


   

Sodium lauroyl glutamate

Sodium lauroyl glutamate

C17H30NNaO5 (351.202157)


   

1H-Benzimidazole,2-[1-[(1-cyclopentyl-1H-tetrazol-5-yl)methyl]-4-piperidinyl]-(9CI)

1H-Benzimidazole,2-[1-[(1-cyclopentyl-1H-tetrazol-5-yl)methyl]-4-piperidinyl]-(9CI)

C19H25N7 (351.217133)


   

UV-328

2-(2H-Benzotriazol-2-yl)-4,6-ditertpentylphenol

C22H29N3O (351.2310504)


   

boc-n-me-glu(obzl)-oh

boc-n-me-glu(obzl)-oh

C18H25NO6 (351.168179)


   

Boc-Glu(OBzl)-OMe

Boc-Glu(OBzl)-OMe

C18H25NO6 (351.168179)


   

LY 344864

N-[(6R)-6-(Dimethylamino)-6,7,8,9-tetrahydro-5H-carbazol-3-yl]-4-fluorobenzamide

C21H22FN3O (351.1746814)


LY 344864 is a selective, orally active 5-HT1F receptor agonist with a Ki of 6 nM. LY 344864 is a full agonist producing an effect similar in magnitude to serotonin itself. LY 344864 can cross the blood brain barrier to some extent[1].

   

Phenadoxone

6-morpholin-4-yl-4,4-diphenylheptan-3-one

C23H29NO2 (351.2198174)


C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist

   

Adipiplon

Adipiplon

C18H18FN7 (351.16076400000003)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018377 - Neurotransmitter Agents > D018682 - GABA Agents > D018755 - GABA Agonists C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic

   

Saxagliptin Hydrochloride

Saxagliptin Hydrochloride

C18H26ClN3O2 (351.1713446)


C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor

   

3-[butyl[4-[(4-nitrophenyl)azo]phenyl]amino]propiononitrile

3-[butyl[4-[(4-nitrophenyl)azo]phenyl]amino]propiononitrile

C19H21N5O2 (351.1695166)


   

Z-N-Me-Glu(OtBu)-OH

Z-N-Me-Glu(OtBu)-OH

C18H25NO6 (351.168179)


   

LY 334370

4-Fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide

C21H22FN3O (351.1746814)


D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists LY334370 is a selective 5-HT1F receptor agonist with a Ki of 1.6 nM.

   

Boc-β-homo-Glu(OBzl)-OH

Boc-β-homo-Glu(OBzl)-OH

C18H25NO6 (351.168179)


   

1-(3-AZIDO-2,3-DIDEOXY-5-O-PIVALOYL-BETA-D-ERYTHRO-PENTOFURANOSYL)-THYMINE

1-(3-AZIDO-2,3-DIDEOXY-5-O-PIVALOYL-BETA-D-ERYTHRO-PENTOFURANOSYL)-THYMINE

C15H21N5O5 (351.15426160000004)


   

1,3,5-Trimethyl-2,4,6-Tris(4-pyridyl)benzene

1,3,5-Trimethyl-2,4,6-Tris(4-pyridyl)benzene

C24H21N3 (351.17353860000003)


   
   

N-octyl-3-metylpyridinium hexafluorophosphate

N-octyl-3-metylpyridinium hexafluorophosphate

C14H24F6NP (351.1550466)


   

GLYCYL-leucyl-tyrosine

GLYCYL-leucyl-tyrosine

C17H25N3O5 (351.179412)


   

3-(1-(tert-Butyldimethylsilyl)-1H-indol-5-yl)benzoic acid

3-(1-(tert-Butyldimethylsilyl)-1H-indol-5-yl)benzoic acid

C21H25NO2Si (351.165447)


   

Estradiol 3-sulfamate

Estradiol 3-sulfamate

C18H25NO4S (351.15042100000005)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones

   

Bisegliptin

Bisegliptin

C18H26FN3O3 (351.1958098)


C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor C471 - Enzyme Inhibitor > C783 - Protease Inhibitor

   

prostaglandin E2(1-)

prostaglandin E2(1-)

C20H31O5- (351.2171376)


The conjugate base of prostaglandin E2; major species at pH 7.3.

   

LY 344864 racemate

LY 344864 racemate

C21H22FN3O (351.1746814)


LY 344864 racemate is a 5-HT1F receptor agonist extracted from patent US 5708187 A.

   

N-((1S,trans)-2-Hydroxycyclopentyl)adenosine

N-((1S,trans)-2-Hydroxycyclopentyl)adenosine

C15H21N5O5 (351.15426160000004)


D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058913 - Purinergic Agonists D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents D009676 - Noxae > D000963 - Antimetabolites GR79236 is a highly potent, selective and orally active adenosine A1 receptor agonist with a Kis of 3.1 nM and 1300 nM for A1 and A2 receptors, respectively. GR79236 has anti-nociceptive and anti-inflammatory actions[1][2]. GR79236 is a highly potent, selective and orally active adenosine A1 receptor agonist with a Kis of 3.1 nM and 1300 nM for A1 and A2 receptors, respectively. GR79236 has anti-nociceptive and anti-inflammatory actions[1][2].

   

3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1-methyl-1H-pyrazole-4-carboxamide

3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1-methyl-1H-pyrazole-4-carboxamide

C18H20F3N3O (351.15583860000004)


   

Carbol-Fuchsin

Carbol-Fuchsin

C21H22ClN3 (351.15021620000005)


D004396 - Coloring Agents > D012394 - Rosaniline Dyes

   

8-(Mesitylthio)-9-(pent-4-yn-1-yl)-9H-purin-6-amine

8-(Mesitylthio)-9-(pent-4-yn-1-yl)-9H-purin-6-amine

C19H21N5S (351.15175860000005)


   
   

2-methyl-3-[(2-methyl-1H-indol-3-yl)-(2-pyridinyl)methyl]-1H-indole

2-methyl-3-[(2-methyl-1H-indol-3-yl)-(2-pyridinyl)methyl]-1H-indole

C24H21N3 (351.17353860000003)


   

8-[1-(3-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1,4-dioxa-8-azaspiro[4.5]decane

8-[1-(3-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1,4-dioxa-8-azaspiro[4.5]decane

C19H21N5O2 (351.1695166)


   

(1S,2S,3R,4S,5R,6S)-4-(hydroxymethyl)-6-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}cyclohexane-1,2,3,5-tetrol

(1S,2S,3R,4S,5R,6S)-4-(hydroxymethyl)-6-{[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl]amino}cyclohexane-1,2,3,5-tetrol

C14H25NO9 (351.152924)


   

4-(2-(2-Chlorophenyl)ethyl)amino-8-methoxy-3,10-dimethyl-2,9-dioxatricyclo(4,3,1,0(3,7))decane

4-(2-(2-Chlorophenyl)ethyl)amino-8-methoxy-3,10-dimethyl-2,9-dioxatricyclo(4,3,1,0(3,7))decane

C19H26ClNO3 (351.16011160000005)


   
   

L-Valine, L-phenylalanyl-L-seryl-

L-Valine, L-phenylalanyl-L-seryl-

C17H25N3O5 (351.179412)


   

L-Tyrosyl-L-alanyl-L-valine

L-Tyrosyl-L-alanyl-L-valine

C17H25N3O5 (351.179412)


   

D-Phenylalanyl-N-Benzyl-L-Prolinamide

D-Phenylalanyl-N-Benzyl-L-Prolinamide

C21H25N3O2 (351.194667)


   

(6r)-2-Amino-6-[2-(3-Methoxybiphenyl-3-Yl)ethyl]-3,6-Dimethyl-5,6-Dihydropyrimidin-4(3h)-One

(6r)-2-Amino-6-[2-(3-Methoxybiphenyl-3-Yl)ethyl]-3,6-Dimethyl-5,6-Dihydropyrimidin-4(3h)-One

C21H25N3O2 (351.194667)


   

D-Leucyl-N-(3-Chlorobenzyl)-L-Prolinamide

D-Leucyl-N-(3-Chlorobenzyl)-L-Prolinamide

C18H26ClN3O2 (351.1713446)


   

(2S)-4-Methyl-2-(3-phenylthioureido)-N-((3S)-tetrahydro-2-hydroxy-3-furanyl)pentanamide

(2S)-4-Methyl-2-(3-phenylthioureido)-N-((3S)-tetrahydro-2-hydroxy-3-furanyl)pentanamide

C17H25N3O3S (351.161654)


   

Tamibarotene

Tamibarotene

C22H25NO3 (351.18343400000003)


C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent

   

1H-indazol-3-yl-[2-[6-methyl-4-(methylamino)pyridin-2-yl]morpholin-4-yl]methanone

1H-indazol-3-yl-[2-[6-methyl-4-(methylamino)pyridin-2-yl]morpholin-4-yl]methanone

C19H21N5O2 (351.1695166)


   

(1R,4Z,6S,7S,17R)-4-Ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-2,9-dioxa-14-azatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione

(1R,4Z,6S,7S,17R)-4-Ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-2,9-dioxa-14-azatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione

C18H25NO6 (351.168179)


   

prostaglandin I2(1-)

prostaglandin I2(1-)

C20H31O5- (351.2171376)


D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Conjugate base of prostaglandin I2.

   

thromboxane A2(1-)

thromboxane A2(1-)

C20H31O5- (351.2171376)


Conjugate base of thromboxane A2 arising from deprotonation of the carboxylic acid function. COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

prostaglandin D2(1-)

prostaglandin D2(1-)

C20H31O5- (351.2171376)


A prostaglandin carboxylic acid anion that is the conjugate base of prostaglandin D2., obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(5S,6E,8Z,10E,12E,14R,15S)-5,14,15-Trihydroxyicosa-6,8,10,12-tetraenoate

(5S,6E,8Z,10E,12E,14R,15S)-5,14,15-Trihydroxyicosa-6,8,10,12-tetraenoate

C20H31O5- (351.2171376)


D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents

   

prostaglandin H2(1-)

prostaglandin H2(1-)

C20H31O5- (351.2171376)


Conjugate base of prostaglandin H2.

   

(5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoate

(5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoate

C20H31O5- (351.2171376)


   

15-dehydro-prostaglandin E1(1-)

15-dehydro-prostaglandin E1(1-)

C20H31O5- (351.2171376)


Conjugate base of 15-dehydro-prostaglandin E1.

   

(5S,6Z,8E,10E,12R,14Z)-5,12,20-Trihydroxyicosa-6,8,10,14-tetraenoate

(5S,6Z,8E,10E,12R,14Z)-5,12,20-Trihydroxyicosa-6,8,10,14-tetraenoate

C20H31O5- (351.2171376)


   

2-Azaniumyl-3-hydroxy-15-methylhexadecane-1-sulfonate

2-Azaniumyl-3-hydroxy-15-methylhexadecane-1-sulfonate

C17H37NO4S (351.2443162)


   

13,14-dihydro-15-oxo-prostaglandin E2(1-)

13,14-dihydro-15-oxo-prostaglandin E2(1-)

C20H31O5- (351.2171376)


Conjugate base of 13,14-dihydro-15-oxo-prostaglandin E2.

   

(5S,15S)-5-hydroperoxy-15-HETE(1-)

(5S,15S)-5-hydroperoxy-15-HETE(1-)

C20H31O5- (351.2171376)


5-hydroperoxy-15-HETE(1-) that has 5S,15S configuration. The conjugate base of (5S,15S)-5-hydroperoxy-15-HETE. The major species at pH 7.3.

   

15-dehydroprostaglandin F2alpha

15-dehydroprostaglandin F2alpha

C20H31O5- (351.2171376)


   

(3R, 7S)-12COOH-JA-Ile

(3R, 7S)-12COOH-JA-Ile

C18H25NO6-2 (351.168179)


   
   
   
   
   

(5S,7E,9E,11Z,13E,15S)-15-hydroperoxy-5-hydroxyicosa-7,9,11,13-tetraenoate

(5S,7E,9E,11Z,13E,15S)-15-hydroperoxy-5-hydroxyicosa-7,9,11,13-tetraenoate

C20H31O5- (351.2171376)


   

(5S,6E,8Z,11Z,13E,15R)-5-hydroperoxy-15-hydroxyicosa-6,8,11,13-tetraenoate

(5S,6E,8Z,11Z,13E,15R)-5-hydroperoxy-15-hydroxyicosa-6,8,11,13-tetraenoate

C20H31O5- (351.2171376)


   

methyl (1S,16S,20S)-16-methyl-17-oxa-3-aza-13-azoniapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,14,18-hexaene-19-carboxylate

methyl (1S,16S,20S)-16-methyl-17-oxa-3-aza-13-azoniapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,14,18-hexaene-19-carboxylate

C21H23N2O3+ (351.1708588)


   

IntegerrimineN-oxide

IntegerrimineN-oxide

C18H25NO6 (351.168179)


   

(1R,4E,6S,7S,17R)-4-Ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-2,9-dioxa-14-azatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione

(1R,4E,6S,7S,17R)-4-Ethylidene-7-hydroxy-7-(hydroxymethyl)-6-methyl-2,9-dioxa-14-azatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione

C18H25NO6 (351.168179)


   

Trideca-3,6,9-trienoylcarnitine

Trideca-3,6,9-trienoylcarnitine

C20H33NO4 (351.2409458000001)


   

Trideca-3,5,7-trienoylcarnitine

Trideca-3,5,7-trienoylcarnitine

C20H33NO4 (351.2409458000001)


   

Trideca-5,7,9-trienoylcarnitine

Trideca-5,7,9-trienoylcarnitine

C20H33NO4 (351.2409458000001)


   

Trideca-4,6,8-trienoylcarnitine

Trideca-4,6,8-trienoylcarnitine

C20H33NO4 (351.2409458000001)


   

Trideca-2,5,8-trienoylcarnitine

Trideca-2,5,8-trienoylcarnitine

C20H33NO4 (351.2409458000001)


   

Trideca-2,4,6-trienoylcarnitine

Trideca-2,4,6-trienoylcarnitine

C20H33NO4 (351.2409458000001)


   

Trideca-6,8,10-trienoylcarnitine

Trideca-6,8,10-trienoylcarnitine

C20H33NO4 (351.2409458000001)


   

Trideca-7,9,11-trienoylcarnitine

Trideca-7,9,11-trienoylcarnitine

C20H33NO4 (351.2409458000001)


   

Trideca-4,7,10-trienoylcarnitine

Trideca-4,7,10-trienoylcarnitine

C20H33NO4 (351.2409458000001)


   

Trideca-5,8,11-trienoylcarnitine

Trideca-5,8,11-trienoylcarnitine

C20H33NO4 (351.2409458000001)


   

(3E,5E,9E)-Trideca-3,5,9-trienoylcarnitine

(3E,5E,9E)-Trideca-3,5,9-trienoylcarnitine

C20H33NO4 (351.2409458000001)


   

(2R,3S,5R)-2-[6-[[(1S,2S)-2-Hydroxycyclopentyl]amino]-9-purinyl]-5-(hydroxymethyl)oxolane-3,4-diol

(2R,3S,5R)-2-[6-[[(1S,2S)-2-Hydroxycyclopentyl]amino]-9-purinyl]-5-(hydroxymethyl)oxolane-3,4-diol

C15H21N5O5 (351.15426160000004)


D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058913 - Purinergic Agonists D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents D009676 - Noxae > D000963 - Antimetabolites

   

N-(2-aminophenyl)-1-butyl-4-hydroxy-2-oxo-3-quinolinecarboxamide

N-(2-aminophenyl)-1-butyl-4-hydroxy-2-oxo-3-quinolinecarboxamide

C20H21N3O3 (351.1582836)


   

8-{[butyl(ethyl)amino]methyl}-7-hydroxy-4-phenyl-2H-chromen-2-one

8-{[butyl(ethyl)amino]methyl}-7-hydroxy-4-phenyl-2H-chromen-2-one

C22H25NO3 (351.18343400000003)


   
   

Schizanthine P

Schizanthine P

C18H25NO6 (351.168179)


A natural product found in Schizanthus tricolor.

   
   

N-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-2-(2,3,5-trimethylphenoxy)acetamide

N-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-2-(2,3,5-trimethylphenoxy)acetamide

C20H21N3O3 (351.1582836)


   

4-[(1-methyl-2-oxo-4-quinolinyl)oxy]-N-(4-methyl-2-pyridinyl)butanamide

4-[(1-methyl-2-oxo-4-quinolinyl)oxy]-N-(4-methyl-2-pyridinyl)butanamide

C20H21N3O3 (351.1582836)


   

2-(4-benzoylphenoxy)-N-(4-methylcyclohexyl)acetamide

2-(4-benzoylphenoxy)-N-(4-methylcyclohexyl)acetamide

C22H25NO3 (351.18343400000003)


   

N-(3-allyl-2-hydroxybenzylidene)-4-[(4-methylphenyl)amino]butanohydrazide

N-(3-allyl-2-hydroxybenzylidene)-4-[(4-methylphenyl)amino]butanohydrazide

C21H25N3O2 (351.194667)


   
   

(E)-N-cyclohexyl-3-(4-nitrophenyl)-N-pyridin-2-ylprop-2-enamide

(E)-N-cyclohexyl-3-(4-nitrophenyl)-N-pyridin-2-ylprop-2-enamide

C20H21N3O3 (351.1582836)


   

N-{4-[4-(2-methylbenzoyl)-1-piperazinyl]phenyl}propanamide

N-{4-[4-(2-methylbenzoyl)-1-piperazinyl]phenyl}propanamide

C21H25N3O2 (351.194667)


   

N-[2-(cyclohexen-1-yl)ethyl]-2-(4-oxochromeno[4,3-c]pyrazol-1-yl)acetamide

N-[2-(cyclohexen-1-yl)ethyl]-2-(4-oxochromeno[4,3-c]pyrazol-1-yl)acetamide

C20H21N3O3 (351.1582836)


   

20-hydroxy-6-trans-leukotriene B4(1-)

20-hydroxy-6-trans-leukotriene B4(1-)

C20H31O5- (351.2171376)


A leukotriene anion that is the conjugate base of 20-hydroxy-6-trans-leukotriene B4 arising from deprotonation of the carboxylic acid function; major species at pH 7.3.

   

13,14-dihydro-15-oxolipoxin A4(1-)

13,14-dihydro-15-oxolipoxin A4(1-)

C20H31O5- (351.2171376)


A hydroxy fatty acid anion obtained by deprotonation of the carboxy function of 13,14-dihydro-15-oxolipoxin A4; major species at pH 7.3.

   

4-[3-(2-Phenoxyethoxy)-2-quinoxalinyl]morpholine

4-[3-(2-Phenoxyethoxy)-2-quinoxalinyl]morpholine

C20H21N3O3 (351.1582836)


   

(12S)-hydroperoxy-(14R,15S)-epoxy-(5Z,8Z,10E)-icosatrienoate

(12S)-hydroperoxy-(14R,15S)-epoxy-(5Z,8Z,10E)-icosatrienoate

C20H31O5- (351.2171376)


A polyunsaturated fatty acid anion that is the conjugate base of (12S)-hydroperoxy-(14R,15S)-EET, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(12S)-hydroperoxy-(14S,15R)-epoxy-(5Z,8Z,10E)-icosatrienoate

(12S)-hydroperoxy-(14S,15R)-epoxy-(5Z,8Z,10E)-icosatrienoate

C20H31O5- (351.2171376)


A polyunsaturated fatty acid anion that is the conjugate base of (12S)-hydroperoxy-(14S,15R)-epoxy-(5Z,8Z,10E)-icosatrienoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(5S)-hydroperoxy-(14R,15S)-epoxy-(6E,8Z,11Z)-icosatrienoate

(5S)-hydroperoxy-(14R,15S)-epoxy-(6E,8Z,11Z)-icosatrienoate

C20H31O5- (351.2171376)


A polyunsaturated fatty acid anion that is the conjugate base of (5S)-hydroperoxy-(14R,15S)-epoxy-(6E,8Z,11Z)-icosatrienoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(8S)-hydroperoxy-(14S,15R)-epoxy-(5Z,9E,11Z)-icosatrienoate

(8S)-hydroperoxy-(14S,15R)-epoxy-(5Z,9E,11Z)-icosatrienoate

C20H31O5- (351.2171376)


A polyunsaturated fatty acid anion that is the conjugate base of (8S)-hydroperoxy-(14S,15R)-epoxy-(5Z,9E,11Z)-icosatrienoate, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

20-hydroxy prostaglandin A1

20-hydroxy prostaglandin A1

C20H31O5- (351.2171376)


   

4-[5-(4-methoxyphenyl)-3-isoxazolyl]-N-(2-pyridinylmethyl)butanamide

4-[5-(4-methoxyphenyl)-3-isoxazolyl]-N-(2-pyridinylmethyl)butanamide

C20H21N3O3 (351.1582836)


   

N-[(2-methoxyphenyl)methyl]-2-methyl-3-prop-2-enoxy-6-indazolecarboxamide

N-[(2-methoxyphenyl)methyl]-2-methyl-3-prop-2-enoxy-6-indazolecarboxamide

C20H21N3O3 (351.1582836)


   

6-(3,5-dimethyl-4-isoxazolyl)-N-[(1-methyl-2-piperidinyl)methyl]-4-quinazolinamine

6-(3,5-dimethyl-4-isoxazolyl)-N-[(1-methyl-2-piperidinyl)methyl]-4-quinazolinamine

C20H25N5O (351.2059)


   

2-(Diethylaminomethyl)-4-spiro[1,6-dihydrobenzo[h]quinazoline-5,1-cyclohexane]one

2-(Diethylaminomethyl)-4-spiro[1,6-dihydrobenzo[h]quinazoline-5,1-cyclohexane]one

C22H29N3O (351.2310504)


   
   
   

(5S,6Z,8E,10E,12R,14Z)-5,12,19-trihydroxyicosa-6,8,10,14-tetraenoate

(5S,6Z,8E,10E,12R,14Z)-5,12,19-trihydroxyicosa-6,8,10,14-tetraenoate

C20H31O5- (351.2171376)


   

(5S,6Z,8E,10E,12R,14Z)-5,12,18-trihydroxyicosa-6,8,10,14-tetraenoate

(5S,6Z,8E,10E,12R,14Z)-5,12,18-trihydroxyicosa-6,8,10,14-tetraenoate

C20H31O5- (351.2171376)


   

1-butyl-4-hydroxy-N-(3-methyl-2-pyridinyl)-2-oxo-3-quinolinecarboxamide

1-butyl-4-hydroxy-N-(3-methyl-2-pyridinyl)-2-oxo-3-quinolinecarboxamide

C20H21N3O3 (351.1582836)


   

(5S,6E,8Z,11Z,13E,15S)-15-hydroperoxy-5-hydroxyicosa-6,8,11,13-tetraenoate

(5S,6E,8Z,11Z,13E,15S)-15-hydroperoxy-5-hydroxyicosa-6,8,11,13-tetraenoate

C20H31O5- (351.2171376)


   

(S,S)-5,12-HpHETE(1-)

(S,S)-5,12-HpHETE(1-)

C20H31O5- (351.2171376)


   
   
   
   
   
   

Tyrosyl-isoleucyl-glycine

Tyrosyl-isoleucyl-glycine

C17H25N3O5 (351.179412)


   
   
   
   
   
   
   

beta-D-tyvelosyl-(1->3)-N-acetyl-beta-D-galactosamine

beta-D-tyvelosyl-(1->3)-N-acetyl-beta-D-galactosamine

C14H25NO9 (351.152924)


   

N,N-bis(2-methoxyethyl)-2-(4-methylphenyl)quinazolin-4-amine

N,N-bis(2-methoxyethyl)-2-(4-methylphenyl)quinazolin-4-amine

C21H25N3O2 (351.194667)


   

N-(9-ethyl-3-carbazolyl)-2-(2-oxolanylmethylamino)acetamide

N-(9-ethyl-3-carbazolyl)-2-(2-oxolanylmethylamino)acetamide

C21H25N3O2 (351.194667)


   

2-[(2S,3R,6S)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N,N-dimethylacetamide

2-[(2S,3R,6S)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N,N-dimethylacetamide

C17H22FN3O4 (351.15942640000003)


   

2-[(2S,3S,6R)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N,N-dimethylacetamide

2-[(2S,3S,6R)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N,N-dimethylacetamide

C17H22FN3O4 (351.15942640000003)


   

(1S,5R)-N-(2-fluorophenyl)-7-[4-[(E)-prop-1-enyl]phenyl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide

(1S,5R)-N-(2-fluorophenyl)-7-[4-[(E)-prop-1-enyl]phenyl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide

C21H22FN3O (351.1746814)


   

1-[(2S,3S)-2-(hydroxymethyl)-6-[oxo(2-pyridinyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-1-yl]ethanone

1-[(2S,3S)-2-(hydroxymethyl)-6-[oxo(2-pyridinyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-1-yl]ethanone

C20H21N3O3 (351.1582836)


   

1-[(2S,3R)-2-(hydroxymethyl)-6-[oxo(2-pyridinyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-1-yl]ethanone

1-[(2S,3R)-2-(hydroxymethyl)-6-[oxo(2-pyridinyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-1-yl]ethanone

C20H21N3O3 (351.1582836)


   

2-[(2S,3R,6R)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N,N-dimethylacetamide

2-[(2S,3R,6R)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N,N-dimethylacetamide

C17H22FN3O4 (351.15942640000003)


   

2-[(2R,3S,6S)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N,N-dimethylacetamide

2-[(2R,3S,6S)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N,N-dimethylacetamide

C17H22FN3O4 (351.15942640000003)


   

2-[(2R,3S,6R)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N,N-dimethylacetamide

2-[(2R,3S,6R)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N,N-dimethylacetamide

C17H22FN3O4 (351.15942640000003)


   

2-[(2R,3R,6S)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N,N-dimethylacetamide

2-[(2R,3R,6S)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N,N-dimethylacetamide

C17H22FN3O4 (351.15942640000003)


   

2-[(2S,3S,6S)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N,N-dimethylacetamide

2-[(2S,3S,6S)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N,N-dimethylacetamide

C17H22FN3O4 (351.15942640000003)


   

2-[(2R,3R,6R)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N,N-dimethylacetamide

2-[(2R,3R,6R)-3-[[(3-fluoroanilino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N,N-dimethylacetamide

C17H22FN3O4 (351.15942640000003)


   

1-[(2R,3R)-2-(hydroxymethyl)-6-[oxo(2-pyridinyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-1-yl]ethanone

1-[(2R,3R)-2-(hydroxymethyl)-6-[oxo(2-pyridinyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-1-yl]ethanone

C20H21N3O3 (351.1582836)


   

1-Hydroxy-5-methoxy-3-methyl-6-[[7-(3-methyl-1,3-butadienyl)-1H-indole-3-yl]methyl]pyrazine-2(1H)-one

1-Hydroxy-5-methoxy-3-methyl-6-[[7-(3-methyl-1,3-butadienyl)-1H-indole-3-yl]methyl]pyrazine-2(1H)-one

C20H21N3O3 (351.1582836)


   
   
   
   
   
   
   
   
   
   
   
   
   

5-hydroperoxy-15-HETE(1-)

5-hydroperoxy-15-HETE(1-)

C20H31O5- (351.2171376)


An icosanoid anion that is the conjugate base of 5-hydroperoxy-15-HETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

4,6-diphenyl-N-[(E)-pyridin-3-ylmethylideneamino]pyrimidin-2-amine

4,6-diphenyl-N-[(E)-pyridin-3-ylmethylideneamino]pyrimidin-2-amine

C22H17N5 (351.1483882)


   
   

(5Z,13E,15S,17Z)-9alpha,11alpha,15-Trihydroxyprosta-5,13,17-trien-1-Oate

(5Z,13E,15S,17Z)-9alpha,11alpha,15-Trihydroxyprosta-5,13,17-trien-1-Oate

C20H31O5- (351.2171376)


   

butanethioic acid S-[4-[(6S,10bR)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinolin-6-yl]phenyl] ester

butanethioic acid S-[4-[(6S,10bR)-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinolin-6-yl]phenyl] ester

C22H25NOS (351.165676)


   

(2S)-hydroxy[(9Z,12Z,15Z)-octadeca-9,12,15-trienoylamino]acetic acid

(2S)-hydroxy[(9Z,12Z,15Z)-octadeca-9,12,15-trienoylamino]acetic acid

C20H33NO4 (351.2409458000001)


   

n-Decanal, o-[(pentafluorophenyl)methyl]oxime

n-Decanal, o-[(pentafluorophenyl)methyl]oxime

C17H22F5NO (351.1621462)


   

2-(2H-Benzo[d][1,2,3]triazol-2-yl)-4,6-dipentylphenol

2-(2H-Benzo[d][1,2,3]triazol-2-yl)-4,6-dipentylphenol

C22H29N3O (351.2310504)


   

1H-indazol-3-yl-[(2S)-2-[6-methyl-4-(methylamino)pyridin-2-yl]morpholin-4-yl]methanone

1H-indazol-3-yl-[(2S)-2-[6-methyl-4-(methylamino)pyridin-2-yl]morpholin-4-yl]methanone

C19H21N5O2 (351.1695166)


   

1-[Diethyl[(E)-2-phenylethenyl]silyl]-2-(diethylsilyl)benzene

1-[Diethyl[(E)-2-phenylethenyl]silyl]-2-(diethylsilyl)benzene

C22H31Si2 (351.1964186)


   

(1R,4Z,6R,7R,14R,17R)-4-ethylidene-7-hydroxy-6,7-dimethyl-14-oxido-2,9-dioxa-14-azoniatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione

(1R,4Z,6R,7R,14R,17R)-4-ethylidene-7-hydroxy-6,7-dimethyl-14-oxido-2,9-dioxa-14-azoniatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione

C18H25NO6 (351.168179)


   

pirenzepine

pirenzepine

C19H21N5O2 (351.1695166)


A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents

   

dipivefrin

dipivefrin

C19H29NO5 (351.20456240000004)


S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01EA - Sympathomimetics in glaucoma therapy D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists C78283 - Agent Affecting Organs of Special Senses > C29705 - Anti-glaucoma Agent

   

Am 80

Tamibarotene

C22H25NO3 (351.18343400000003)


C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent Same as: D01418

   

lipoxin B4(1-)

lipoxin B4(1-)

C20H31O5 (351.2171376)


A hydroxy fatty acid anion obtained by the deprotonation of the carboxy group of lipoxin B4: major species at pH 7.3.

   

Am 580

4-{[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid

C22H25NO3 (351.18343400000003)


D009676 - Noxae > D013723 - Teratogens D000970 - Antineoplastic Agents

   

C16 Sphingosine-1-phosphate

C16 Sphingosine-1-phosphate

C16H34NO5P (351.2174484)


   

N-(3-oxo-9Z-hexadecenoyl)-homoserine lactone

N-(3-oxo-9Z-hexadecenoyl)-homoserine lactone

C20H33NO4 (351.2409458000001)


   

19-hydroxyleukotriene B4(1-)

19-hydroxyleukotriene B4(1-)

C20H31O5 (351.2171376)


A leukotriene anion that is the conjugate base of 19-hydroxyleukotriene B4, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

beta-D-Tyvp-(1->3)-beta-D-GalpNAc

beta-D-Tyvp-(1->3)-beta-D-GalpNAc

C14H25NO9 (351.152924)


An amino disaccharide consisting of N-acetyl-beta-D-galactosamine having a beta-D-tyvelosyl residue attached at the 3-position.

   

(5S)-hydroxy-(15S)-hydroperoxy-(6E,8Z,11Z,13E)-icosatetraenoate

(5S)-hydroxy-(15S)-hydroperoxy-(6E,8Z,11Z,13E)-icosatetraenoate

C20H31O5 (351.2171376)


An hydroperoxy(hydroxy)icosatetraenoate that is the conjugate base of (5S)-hydroxy-(15S)-hydroperoxy-(6E,8Z,11Z,13E)-icosatetraenoic acid; major species at pH 7.3.

   

lipoxin A4(1-)

lipoxin A4(1-)

C20H31O5 (351.2171376)


A hydroxy fatty acid anion obtained by deprotonation of the carboxy function of lipoxin A4: major species at pH 7.3.

   

18-hydroxyleukotriene B4(1-)

18-hydroxyleukotriene B4(1-)

C20H31O5 (351.2171376)


A leukotriene anion that is the conjugate base of 18-hydroxyleukotriene B4, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

20-hydroxy-leukotriene B4(1-)

20-hydroxy-leukotriene B4(1-)

C20H31O5 (351.2171376)


Conjugate base of 20-hydroxy-leukotriene B4 arising from deprotonation of the carboxylic acid function.

   

hexadecasphing-4-enine-1-phosphate

hexadecasphing-4-enine-1-phosphate

C16H34NO5P (351.2174484)


A sphingoid 1-phosphate that is hexadecasphing-4-enine substituted by a phospho group at position 1.

   
   

Dehydro-geissoschizine

Dehydro-geissoschizine

C21H23N2O3 (351.1708588)


   
   
   
   
   
   
   
   
   

C16 Sphingosine 1-phosphate

C16 Sphingosine 1-phosphate

C16H34NO5P (351.2174484)


   
   

NAB-14

NAB-14

C20H21N3O3 (351.1582836)


NAB-14 is a potent, selective, orally active and non-competitive GluN2C/2D antagonists with an IC50 of 580 nM for GluN1/GluN2D. NAB-14 shows >800-fold selective for recombinant GluN2C and GluN2D over GluN2A and GluN2B. NAB-14 can cross the blood-brain-barrier[1].

   

NPY5RA-972

NPY5RA-972

C21H25N3O2 (351.194667)


NPY5RA-972 is an orally active, central nervous system (CNS) penetrating, potent and selective NPY Y5 receptor antagonist that prevents feeding driven by activation of this receptor[1].